stockrowPfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.
- Revenue
- −0.43%
- EPS
- −7.98%
- Free cash flow
- +20.0%
- Total debt
- +1.55%
Quarter to September 2026, against a year earlier
Follow PFE
Alert me
Pfizer Inc. (PFE) Current ratio
Pfizer Inc.'s current ratio at the end of the quarter to 30 September 2026 was 1.4×, up 0.3× from fiscal 2025 (1.2×). Over the past ten years it has ranged from 0.9× (fiscal 2019) to 1.6× (fiscal 2018); the current reading is higher than 27% of that period. That is in line with the Drug Manufacturers General industry median of 1.4× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 1.2× | (0.97%) |
| FY2024 | 1.2× | 29.18% |
| FY2023 | 0.9× | (25.47%) |
| FY2022 | 1.2× | (13.04%) |
| FY2021 | 1.4× | 3.40% |
| FY2020 | 1.4× | 53.86% |
| FY2019 | 0.9× | (43.89%) |
| FY2018 | 1.6× | 15.90% |
| FY2017 | 1.4× | 8.01% |
| FY2016 | 1.3× | (15.99%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 1.4× | 11.98% |
| Jun 2026 | 1.3× | 1.62% |
| Mar 2026 | 1.2× | 7.48% |
| Dec 2025 | 1.2× | (9.54%) |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| BMY Bristol Myers Squibb Company compare | 1.6× |
| AMGN Amgen Inc. compare | 1.5× |
| PFE Pfizer Inc. | 1.4× |
| GILD Gilead Sciences, Inc. compare | 1.4× |
| SNY Sanofi compare | 1.1× |
| AZN AstraZeneca PLC compare | 1.0× |
| NVS Novartis AG compare | 0.9× |
| NVO Novo Nordisk A/S compare | 0.9× |
| GSK GSK PLC Sponsored ADR compare | 0.9× |
| Drug Manufacturers General industry median | 1.4× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on PFE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement